The RV144 trial was the only to demonstrate some level of efficacy (~31.2%) against HIV infection by inducing env-specific CD4+ T cells as well as antibodies that were able to bind to HIV, but not to neutralize it (1, 2). This evidence concerns the gene CD4 and HIV infectious disease.